Opendata, web and dolomites


Next generation eco-friendly, microbiome preserving and reduced resistance therapeutics

Total Cost €


EC-Contrib. €






 NEXTER project word cloud

Explore the words cloud of the NEXTER project. It provides you a very rough idea of what is the project "NEXTER" about.

plan    commercialize    designing    synthetic    prevent    moieties    rapid    poc    pharma    additional    environment    ip    bacterial    environmental    distinction    mechanisms    spread    resistance    perfecting    human    medicine    primary    species    pharmaceuticals    contaminate    cells    microbiome    revolutionary    stop    negligible    outcome    selective    companies    network    amr    dozes    powerful    discovered    causing    aureus    escape    contamination    antibiotics    commercialization    designed    efforts    preserve    compounds    least    protecting    strategy    enterococcus    inhibit    protein    beneficial    ribosome    lower    alongside    pathogenic    drugs    company    decrease    emergence    chemical    selectivity    strategic    hence    desperately    capacity    modern    technological    harm    attaching    unpredictable    biosynthesis    delivered    innovative    degradable    drug    antibiotic    motifs    global    shown    partnership    resistant    clinically    ribosomal    strengthen    pathogen    bacteria    attempt    antimicrobial    pathogens    strains    health    structural    pseudomonas   

Project "NEXTER" data sheet

The following table provides information about the project.


Organization address
address: HERZL STREET 234
postcode: 7610001

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2020-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 150˙000.00


 Project objective

The rapid emergence and spread of Multi-drug Antimicrobial Resistance (AMR), alongside the negligible efforts of the major pharmaceuticals companies in the development of new antibiotics, result in a major global concern of modern medicine. Moreover, the currently clinically used antibiotics contaminate the environment and may harm the human microbiome, causing unpredictable health concerns. We discovered that by targeting species-specific ribosome unique structural motifs, identified by us, using our designed degradable novel synthetic lead compounds, it is possible to inhibit protein biosynthesis in bacteria. Our approach should enable distinction between pathogenic and non-pathogenic bacteria and between bacterial and human ribosome. This drug selectivity should decrease resistance, preserve the beneficial microbiome and allow usage of lower antibiotics dozes. Furthermore, the designed degradable lead compounds should prevent additional environmental contamination. Hence, our approach allows designing innovative powerful selective antibiotics that escape the existing resistance mechanisms. Several of the primary designed compounds shown to stop the growth of the multi-resistant S. aureus human pathogen were delivered into the bacterial cells by attaching specific chemical moieties to them. In this PoC we plan to design similar compounds for other human pathogens, such as Enterococcus and Pseudomonas species, where revolutionary effective antibiotic drugs against their resistant strains is desperately needed. In addition to the technological PoC in this project, we will attempt pre-commercialization studies aiming at perfecting the commercialization strategy, protecting the IP and strengthen the network for best possible commercialization outcome. The general objective is to establish at least one strategic partnership with a pharma company which has the capacity to further test, develop and commercialize antibiotics that exploit ribosomal novel unique targets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEXTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEXTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Mass Politics of Disintegration

Read More  


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DigitalValues (2019)

The Construction of Values in Digital Spheres

Read More